Xenon Pharmaceuticals (XENE) is preparing to file a new drug application for azetukalner in September 2026, according to the company’s comments at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Sept. 9.
Azetukalner, a Kv7 potassium channel modulator for focal onset seizures, showed its strongest placebo-adjusted efficacy at the 25-milligram dose in the X-TOLE2 trial, CFO Tucker Kelly said. Across Phase IIb testing, the 10 mg dose produced adverse event rates comparable to placebo, while X-TOLE3, now enrolling roughly 360 patients (300 outside Japan and 60 in Japan), is expected to complete enrollment outside Japan by late 2024.
On pricing, Xenon aims to position azetukalner north of the $15,000 to $18,000 annual range seen with competitor drugs XCOPRI (about $15,400 annually gross) and BRIVIACT (around $18,000 before generics emerged in 2024). Kelly described the upcoming launch trajectory as “low and slow.”
The company’s commercial team currently numbers about 150 people, including more than 75 sales representatives and 8 to 10 medical science liaisons, targeting a physician universe of approximately 7,000 to 8,000 prescribers in the U.S.—roughly 1,500 of whom are epileptologists. XCOPRI, marketed by SK Life Science, has reached about $600 million in annualized U.S. revenue, with peak-sales guidance of $2 billion. Vimpat generated about $1.3 billion in U.S. revenue before its patent expired in 2021.
Xenon also updated progress on its other assets. An update on receptor occupancy and early safety signals for XEN1701, its first NaV1.7 inhibitor, is expected later in 2024, with a proof-of-concept study in acute pain planned for 2025. The Phase III X-NOVA trial in major depressive disorder uses HAM-D 17 as its primary endpoint, targeting approximately a 2-point placebo separation.
The company disclosed it maintains a balance sheet with more cash than debt and a current ratio above 21, rating its overall Financial Health Score as “FAIR.” Xenon stated its goal is to become a fully integrated commercial biopharma company by late 2027.
